FIRST QUARTER 2026 HIGHLIGHTS
- GAAP Net loss of
$(0.00) per share, NAREIT FFO of$0.35 per share, Normalized FFO of$0.41 per share, and FAD of$112.9 million (payout ratio of 75%) - Same store cash NOI growth of +6.9%, tenant retention of 93.5% and+4.2% cash leasing spreads
- First quarter lease executions totaled 2.0 million square feet across same store properties and redevelopment projects, including 286,000 square feet of new lease executions
- During the first quarter, the Company completed total transactions of approximately
$125 million , including the first new acquisition in the KKR joint venture since formation for$89 million ($18 million at the Company's pro rata share) and dispositions of$33 million - Net Debt to Adjusted EBITDA of 5.5x adjusted for expected mortgage note receivable repayment in the second quarter
- Repurchased 5.7 million shares of common stock at an average price of
$17.38 per share for a total of$100 million - Received
$400 million commitments from existingBank Group for a new unsecured delayed draw term loan expected to close inMay 2026 ; the Company will have the ability to draw the proceeds at any time over the 12-month period post-closing - As part of ongoing Board Refreshment initiatives, longtime director
Jay Leupp announced he will retire following our upcoming Annual Meeting of Shareholders onMay 19, 2026
FIRST QUARTER 2026 RESULTS
| FIRST QUARTER ENDED | |||||||||||||
| 2026 | 2025 | ||||||||||||
| (in thousands, except per share amounts) | AMOUNT | PER SHARE | AMOUNT | PER SHARE | |||||||||
| GAAP Net loss | $(56 | ) | $(0.00 | ) | $(44,873 | ) | $(0.13 | ) | |||||
| NAREIT FFO, diluted | |||||||||||||
| Normalized FFO, diluted | |||||||||||||
LEASING ACTIVITY
During the first quarter, the Company executed 291 new and renewal leases for 2.0 million square feet with a weighted average lease term of 7.7 years and average annual escalators of 3.1%. Key highlights include:
Atlanta, GA. 176,000 square feet of new and renewal leases withWellstar Health System , maintaining greater than 90% occupancy across six on-campus MOBs- Charlotte, NC. Renewed 153,600 square feet with
Advocate Health across five buildings that are 93% occupied Charleston, SC . Renewed 54,600 square feet withMUSC Health across two buildings that are 100% occupiedAlbany, NY . Executed two new leases withSt. Peter's Health for clinic space and an ASC totaling 63,500 square feet in a redevelopment project- Various. Renewed approximately 736,000 square feet at eight single-tenant properties with a weighted average remaining lease term of less than three years; on average, extended the leases by nearly 10 years with strong cash leasing spreads
CAPITAL ALLOCATION
Acquisitions and Dispositions
During the first quarter, the Company completed approximately
Birmingham, AL . Acquired a state-of-the-art MOB attached to a market-leading hospital with an existing joint venture partner for$89 million ($18 million investment at share). The Company now owns two properties at this hospital campus and nearly 650,000 square feet in the marketOklahoma City , OK. Opportunistically disposed of two assets for$12 million in a direct sale to the affiliated health system
Development and Redevelopment
During the first quarter, the Company added two new redevelopment projects (
- Charlotte, NC. Completed redevelopment of two MOBs in a rapidly growing market adjacent to the
Novant Health Huntersville Medical Center . The$35 million project is 98% leased by a mix of hospital and physician practices including cardiology, oncology, women's health, dermatology and imaging Boston, MA. Commenced a 155,000 square foot redevelopment connected toTufts Medical Center in downtownBoston . The$25 million project will modernize the fully leased property and provide a space for Tufts Medicine to deliver world-class healthcare
Balance Sheet
- Net Debt to Adjusted EBITDA of 5.5x. As of
March 31, 2026 , the Company had approximately$1.2 billion of liquidity on the revolving facility and cash on hand - In the first quarter, the Company repurchased 5.7 million shares of common stock at an average price of
$17.38 per share for a total of$100 million - On
February 12, 2026 ,Healthcare Realty established its inaugural commercial paper program, with a total size of up to$600 million . At the end of the first quarter, the Company had$251 million outstanding at a weighted average interest rate of 4.2%, representing over 30bps savings compared to our drawn revolving facility rate - Extended
$400 million swaps toJanuary 2029 at a fixed SOFR rate of 3.3% - The Company has received
$400 million of commitments from its existingBank Group for a new unsecured delayed draw term loan that is expected to close inMay 2026 . The Company will have the ability to draw the proceeds at any time over the 12-month period post-closing
BOARD REFRESHMENT
As part of the Company’s ongoing Board Refreshment initiatives, longtime director
DIVIDEND
The Board unanimously approved a common stock dividend in the amount of
GUIDANCE
The Company's increased 2026 per share estimated guidance ranges are as follows:
| 2026 GUIDANCE | ||||||||||
| ACTUAL | PRIOR | CURRENT | ||||||||
| 1Q 2026 | LOW | HIGH | LOW | HIGH | ||||||
| Earnings per share | $(0.00 | ) | $(0.05 | ) | $(0.05 | ) | ||||
| NAREIT FFO per share | ||||||||||
| Normalized FFO per share | ||||||||||
| Same Store Cash NOI growth | 6.9 % | 3.5 % | 4.5 % | 3.75 % | 4.75 % | |||||
The 2026 annual guidance range reflects the Company's view of current and future market conditions, including assumptions with respect to rental rates, occupancy levels, interest rates, and operating and general and administrative expenses. The Company's guidance does not contemplate impacts from gains or losses from dispositions, potential impairments, or debt extinguishment costs, if any. The Company's guidance also does not include any future acquisitions, developments or share issuances or repurchases, other than as discussed in the detailed guidance assumptions on Page 11 of the 1Q 2026 Supplemental. There can be no assurance that the Company's actual results will not be materially higher or lower than these expectations. If actual results or timing vary from these assumptions, the Company's expectations may change. See Page 11 of the 1Q 2026 Supplemental for additional details and assumptions.
EARNINGS CALL
On
Simultaneously, a webcast of the conference call will be available to interested parties at https://investors.healthcarerealty.com/corporate-profile/webcasts under the Investor Relations section. A webcast replay will be available following the call at the same address.
Live Conference Call Access Details:
- Domestic Dial-In Number: +1 800-715-9871 access code 4950066
- All Other Locations: +1 646-307-1963 access code 4950066
Replay Information:
- Domestic Dial-In Number: +1 800-770-2030 access code 4950066
- All Other Locations: +1 609-800-9909 access code 4950066
ABOUT
For additional information contact InvestorRelations@healthcarerealty.com.
Additional information regarding the Company, including this quarter's operations, can be found at www.healthcarerealty.com. In addition to the historical information contained within, this press release contains certain forward-looking statements with respect to the Company. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “target,” “intend,” “plan,” “estimate,” “project,” “continue,” “should,” “could," "budget" and other comparable terms. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Such risks and uncertainties include, among other things, the following: the Company’s expected results may not be achieved; risks related to future opportunities and plans for the Company, including the uncertainty of expected future financial performance and results of the Company; pandemics or other health crises; increases in interest rates; the availability and cost of capital at expected rates; competition for quality assets; negative developments in the operating results or financial condition of the Company's tenants, including, but not limited to, their ability to pay rent; the Company's ability to reposition or sell facilities with profitable results; the Company's ability to release space at similar rates as vacancies occur; the Company's ability to renew expiring leases; government regulations affecting tenants' Medicare and Medicaid reimbursement rates and operational requirements; unanticipated difficulties and/or expenditures relating to future acquisitions and developments; changes in rules or practices governing the Company's financial reporting; the Company may be required under purchase options to sell properties and may not be able to reinvest the proceeds from such sales at rates of return equal to the return received on the properties sold; uninsured or underinsured losses related to casualty or liability; the incurrence of impairment charges on its real estate properties or other assets; other legal and operational matters; and other risks and uncertainties affecting the Company, including those described from time to time under the caption “Risk Factors” and elsewhere in the Company’s filings and reports with the
| Balance Sheet | ||||
| AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA | ||||
| ASSETS | ||||
| 1Q 2026 | 4Q 2025 | |||
| Real estate properties | ||||
| Land | ||||
| Buildings and improvements | 8,541,368 | 8,514,165 | ||
| Lease intangibles | 424,502 | 455,254 | ||
| Personal property | 7,316 | 7,056 | ||
| Investment in financing receivables, net | 122,346 | 123,249 | ||
| Financing lease right-of-use assets | 74,703 | 75,083 | ||
| Land held for development | 57,799 | 57,535 | ||
| Total real estate investments | 10,288,330 | 10,292,596 | ||
| Less accumulated depreciation and amortization | (2,468,461 | ) | (2,397,795 | ) |
| Total real estate investments, net | 7,819,869 | 7,894,801 | ||
| Cash and cash equivalents | 26,235 | 26,172 | ||
| Assets held for sale, net | 123,411 | 143,580 | ||
| Operating lease right-of-use assets | 202,710 | 204,906 | ||
| Investments in unconsolidated joint ventures | 467,459 | 453,607 | ||
| Other assets, net | 508,480 | 487,795 | ||
| Total assets | ||||
| LIABILITIES, REDEEMABLE NON-CONTROLLING INTERESTS, AND STOCKHOLDERS' EQUITY | ||||
| Liabilities | ||||
| Notes and bonds payable | ||||
| Accounts payable and accrued liabilities | 137,712 | 211,071 | ||
| Liabilities of properties held for sale | 13,576 | 15,160 | ||
| Operating lease liabilities | 162,380 | 162,922 | ||
| Financing lease liabilities | 73,679 | 73,130 | ||
| Other liabilities | 159,888 | 160,530 | ||
| Total liabilities | 4,651,153 | 4,534,236 | ||
| Redeemable non-controlling interests | 3,339 | 3,252 | ||
| Stockholders' equity | ||||
| Preferred stock, | — | — | ||
| Common stock, | 3,465 | 3,516 | ||
| Additional paid-in capital | 9,040,690 | 9,137,257 | ||
| Accumulated other comprehensive (loss) income | (2,421 | ) | (5,174 | ) |
| Cumulative net income attributable to common stockholders | 128,182 | 128,238 | ||
| Cumulative dividends | (4,730,746 | ) | (4,646,944 | ) |
| Total stockholders' equity | 4,439,170 | 4,616,893 | ||
| Non-controlling interest | 54,502 | 56,480 | ||
| Total equity | 4,493,672 | 4,673,373 | ||
| Total liabilities, redeemable non-controlling interests, and stockholders' equity | ||||
| Income Statements | ||||||
| AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA | ||||||
| FIRST QUARTER ENDED | FULL YEAR | |||||
| 2026 | 2025 | 2025 | ||||
| Revenues | ||||||
| Rental income | ||||||
| Interest income | 3,712 | 3,731 | 14,275 | |||
| Other operating | 7,703 | 6,389 | 28,215 | |||
| Total revenues | 278,990 | 298,977 | 1,180,546 | |||
| Expenses | ||||||
| Property operating | 100,058 | 109,897 | 424,855 | |||
| General and administrative | 17,343 | 13,530 | 72,569 | |||
| Normalizing items 1 | (7,562 | ) | (502 | ) | (26,318 | ) |
| Normalized general and administrative | 9,781 | 13,028 | 46,251 | |||
| Transaction costs | 937 | 1,011 | 2,029 | |||
| Depreciation and amortization | 128,985 | 156,035 | 588,186 | |||
| Total expenses | 247,323 | 280,473 | 1,087,639 | |||
| Other income (expense) | ||||||
| Interest expense before merger-related fair value | (32,899 | ) | (44,366 | ) | (166,396 | ) |
| Merger-related fair value adjustment | (10,991 | ) | (10,446 | ) | (42,593 | ) |
| Interest expense | (43,890 | ) | (54,812 | ) | (208,989 | ) |
| Gain on sales of real estate properties and other assets | 10,777 | 2,904 | 235,389 | |||
| Loss on extinguishment of debt | (21 | ) | — | (451 | ) | |
| Impairment of real estate assets and credit loss recoveries (reserves) | 984 | (12,081 | ) | (364,598 | ) | |
| Equity income (loss) from unconsolidated joint ventures | 496 | 1 | (188 | ) | ||
| Interest and other income (expense), net | 8 | 95 | (3,555 | ) | ||
| Total other income (expense) | (31,646 | ) | (63,893 | ) | (342,392 | ) |
| Net income (loss) | $(45,389 | ) | $(249,485 | ) | ||
| Net (income) loss attributable to non-controlling interests | (77 | ) | 516 | 3,414 | ||
| Net loss attributable to common stockholders | $(56 | ) | $(44,873 | ) | $(246,071 | ) |
| Basic earnings per common share | $(0.00 | ) | $(0.13 | ) | $(0.71 | ) |
| Diluted earnings per common share | $(0.00 | ) | $(0.13 | ) | $(0.71 | ) |
| Weighted average common shares outstanding - basic | 347,439 | 349,539 | 349,798 | |||
| Weighted average common shares outstanding - diluted 2 | 347,439 | 349,539 | 349,798 | |||
1 Normalizing items primarily include restructuring, severance-related costs and other.
2 Potential common shares are not included in the computation of diluted earnings per share when a loss exists (or when dividends paid are greater than income), as the effect would be an antidilutive per share amount. As a result, the outstanding limited partnership units in the Company's operating partnership ("OP"), totaling 4,278,028 units were not included.
| FFO, Normalized FFO and FAD | ||||||
| AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA | ||||||
| FIRST QUARTER ENDED | FULL YEAR | |||||
| 2026 | 2025 | 2025 | ||||
| Net loss attributable to common stockholders | $(56 | ) | $(44,873 | ) | $(246,071 | ) |
| Net loss attributable to common stockholders/diluted share | $(0.00 | ) | $(0.13 | ) | $(0.71 | ) |
| Gain on sales of real estate assets | (10,777 | ) | (2,904 | ) | (235,389 | ) |
| Impairments of real estate assets | 16 | 10,145 | 361,090 | |||
| Real estate depreciation and amortization | 127,921 | 155,288 | 586,146 | |||
| Non-controlling loss from operating partnership units | (10 | ) | (599 | ) | (3,497 | ) |
| Unconsolidated JV depreciation, amortization and impairment | 6,604 | 6,717 | 27,769 | |||
| NAREIT FFO | ||||||
| NAREIT FFO per common share - diluted | $0.35 | $0.35 | $1.38 | |||
| Transaction costs | 937 | 1,011 | 2,029 | |||
| Debt financing costs | 116 | — | 5,107 | |||
| Restructuring and severance-related charges | 7,562 | 502 | 26,318 | |||
| Merger-related fair value adjustment | 10,991 | 10,446 | 42,593 | |||
| Other | 1,078 | 1,989 | 2,851 | |||
| Normalized FFO | ||||||
| Normalized FFO per common share - diluted | $0.41 | $0.39 | $1.61 | |||
| Non-real estate depreciation and amortization | 663 | 1,269 | 6,114 | |||
| Non-cash interest amortization, net | 1,367 | 1,217 | 5,126 | |||
| Straight-line amortization, net | (10,291 | ) | (7,891 | ) | (29,392 | ) |
| Stock-based compensation | 3,927 | 3,028 | 13,609 | |||
| Unconsolidated JV non-cash items | (89 | ) | (253 | ) | (1,420 | ) |
| Other | — | 94 | 952 | |||
| Maintenance capex | (27,101 | ) | (32,966 | ) | (115,633 | ) |
| FAD | ||||||
| Quarterly dividends and OP distributions | ||||||
| FFO wtd avg common shares outstanding - diluted 1 | 352,211 | 353,522 | 354,454 | |||
1 The Company utilizes the treasury stock method, which includes the dilutive effect of nonvested share-based awards outstanding of 493,403 for the three months ended
Non-GAAP Measures
Management considers funds from operations ("FFO"), FFO per share, normalized FFO, normalized FFO per share, and funds available for distribution ("FAD") to be useful non-GAAP measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure historical financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors.
The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income (determined in accordance with GAAP), as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities (determined in accordance with GAAP) as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs.
FFO and FFO per share are operating performance measures adopted by the
Management believes FFO, FFO per share, Normalized FFO, Normalized FFO per share, and FAD provide an understanding of the operating performance of the Company’s properties without giving effect to certain significant non-cash items, including depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization, gains or losses from sales of real estate, and other normalizing items that are unusual and infrequent, FFO, FFO per share, Normalized FFO, Normalized FFO per share and FAD can facilitate comparisons of operating performance between periods. The Company reports these measures because they have been observed by management to be the predominant measures used by the REIT industry and by industry analysts to evaluate REITs and because these measures are consistently reported, discussed, and compared by research analysts in their notes and publications about REITs.
Cash NOI and Same Store Cash NOI are key performance indicators. Management considers these to be supplemental measures that allow investors, analysts and Company management to measure unlevered property-level operating results. The Company defines Cash NOI as rental income plus interest from financing receivables less property operating expenses. Cash NOI excludes non-cash items such as above and below market lease intangibles, straight-line rent, lease inducements, lease termination fees, financing receivable amortization, tenant improvement amortization and leasing commission amortization. Cash NOI is historical and not necessarily indicative of future results.
Same Store Cash NOI compares Cash NOI for stabilized properties. Stabilized properties are properties that have been included in operations for the duration of the year-over-year comparison period presented. Accordingly, stabilized properties exclude properties that were recently acquired or disposed of, properties classified as held for sale, properties undergoing redevelopment, and newly redeveloped or developed properties.
The Company utilizes the redevelopment classification for properties where management has approved a change in strategic direction through the application of additional resources, including an amount of capital expenditures significantly above routine maintenance and capital improvement expenditures.
Any recently acquired property will be included in the same store pool once the Company has owned the property for five full quarters. Newly developed or redeveloped properties will be included in the same store pool five full quarters after substantial completion.
